-
公开(公告)号：US20240050430A1
公开(公告)日：2024-02-15
申请号：US18213464
申请日：2023-06-23
Applicant: Amgen Inc.
Inventor： John Gordon ALLEN , Jennifer Rebecca ALLEN , Ana Elena MINATTI , Qiufen XUE , Ryan Paul WURZ , Christopher M. TEGLEY , Alexander J. PICKRELL , Thomas T. NGUYEN , Vu Van MA , Patricia LOPEZ , Longbin LIU , David John KOPECKY , Michael J. FROHN , Ning CHEN , Jian Jeffrey CHEN , Aaron C. SIEGMUND , Albert AMEGADZIE , Nuria A. TAMAYO , Shon BOOKER , Clifford GOODMAN , Mary WALTON , Nobuko NISHIMURA , Youngsook SHIN , Jonathan D. LOW , Victor J. CEE , Anthony B. REED , Hui-Ling WANG , Brian Alan LANMAN
IPC: A61K31/517 , A61P35/00 , A61K31/4985 , A61K39/395 , C07D403/04 , C07D471/04
CPC classification number: A61K31/517 , A61P35/00 , C07D471/04 , A61K39/39558 , C07D403/04 , A61K31/4985
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20240294551A1
公开(公告)日：2024-09-05
申请号：US18614911
申请日：2024-03-25
Applicant: AMGEN INC.
Inventor： Ryan Paul Wurz , Yunxiao LI , Primali Vasundera NAVARATNE , Jose M. MEDINA , Ning CHEN , Liping PETTUS , Xiaofen LI , John STELLWAGEN , Kexue LI , Brian Alan LANMAN , Michael M. YAMANO , Wei ZHAO , Benjamin WIGMAN , Fabien EMMETIERE , Albert K. AMEGADZIE , Christopher P. MOHR , Aaron C. SIEGMUND , Rene RAHIMOFF , Zhichen WU , Adriano BAUER , Andrew SMALIGO , Quentin Tercenio , Qingyian Liu , Shon K. Booker
IPC: C07D519/00 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/551 , A61K31/553 , C07D471/22 , C07D498/22 , C07D513/22
CPC classification number: C07D519/00 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/551 , A61K31/553 , C07D471/22 , C07D498/22 , C07D513/22
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′:
wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.-
公开(公告)号：US20220175782A1
公开(公告)日：2022-06-09
申请号：US17579359
申请日：2022-01-19
Applicant: AMGEN INC.
Inventor： John Gordon ALLEN , Brian Alan LANMAN , Jian CHEN , Anthony B. REED , Victor J. CEE , Longbin LIU , Patricia LOPEZ , Ryan Paul WURZ , Thomas T. NGUYEN , Shon BOOKER , Jennifer Rebecca ALLEN , Margaret CHU-MOYER , Albert AMEGADZIE , Ning CHEN , Clifford GOODMAN , Jonathan D. LOW , Vu Van MA , Ana Elena MINATTI , Nobuko NISHIMURA , Alexander J. PICKRELL , Hui-Ling WANG , Youngsook SHIN , Aaron C. SIEGMUND , Kevin C. YANG , Nuria A. TAMAYO , Mary WALTON , Qiufen XUE
IPC: A61K31/519 , A61K31/551 , A61K39/395 , A61P35/00
Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
4.发明申请公开(公告)号：US20170267673A1
公开(公告)日：2017-09-21
申请号：US15354877
申请日：2016-11-17
Applicant: AMGEN INC.
Inventor： Jennifer R. ALLEN , Albert AMEGADZIE , Matthew P. BOURBEAU , James A. BROWN , Jian J. CHEN , Yuan CHENG , Michael J. FROHN , Angel GUZMAN-PEREZ , Paul E. HARRINGTON , Longbin LIU , Qingyian LIU , Jonathan D. LOW , Vu Van MA , James R. MANNING , Ana Elena MINATTI , Thomas T. NGUYEN , Nobuko NISHIMURA , Mark H. NORMAN , Liping H. PETTUS , Alexander J. PICKRELL , Wenyuan QIAN , Shannon RUMFELT , Robert M. RZASA , Aaron C. SIEGMUND , Markian M. STEC , Ryan D. WHITE , Qiufen XUE
IPC: C07D417/12 , C07D417/14 , C07D471/04 , C07D279/08 , C07D417/04 , C07D513/10
CPC classification number: C07D417/12 , C07D279/08 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/10
Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
-
5.发明申请Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use 有权环丙基稠合噻嗪-2-胺化合物作为β-分泌酶抑制剂和使用方法公开(公告)号：US20160046618A1
公开(公告)日：2016-02-18
申请号：US14819256
申请日：2015-08-05
Applicant: AMGEN INC.
Inventor： Jennifer R. ALLEN , Albert AMEGADZIE , Matthew P. BOURBEAU , James A. BROWN , Jian J. CHEN , Yuan CHENG , Michael J. FROHN , Angel GUZMAN-PEREZ , Paul E. HARRINGTON , Longbin LIU , Qingyian LIU , Jonathan D. LOW , Vu Van MA , James MANNING , Ana Elena MINATTI , Thomas T. NGUYEN , Nobuko NISHIMURA , Mark H. NORMAN , Liping H. PETTUS , Alexander J. PICKRELL , Wenyuan QIAN , Shannon RUMFELT , Robert M. RZASA , Aaron C. SIEGMUND , Markian M. STEC , Ryan D. WHITE , Qiufen XUE
IPC: C07D417/12 , C07D471/04 , C07D513/10 , C07D417/14
CPC classification number: C07D417/12 , C07D279/08 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/10
Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
Abstract translation: 本发明提供了一类可用于调节β-分泌酶（BACE）活性的化合物。 所述化合物具有通式I：其中式I中的变量A4，A5，A6，A8以及R 1，R b，R 1，R 2，R 3和R 7各自独立地定义。 本发明还提供包含该化合物的药物组合物，以及该化合物和组合物用于治疗由BACE的生物学活性产生的与A-β斑块形成和沉积有关的病症和/或病症的用途。 这种BACE介导的疾病包括例如阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。 本发明还提供式II和III的化合物及其分子式实施方案，用于制备本发明化合物的中间体和方法。
-
Patent Agency Ranking
公开(公告)号：US20210171529A1
公开(公告)日：2021-06-10
申请号：US17103350
申请日：2020-11-24
Applicant: Amgen Inc.
Inventor： Jennifer R. ALLEN , Albert AMEGADZIE , Matthew P. BOURBEAU , Ning CHEN , Clifford GOODMAN , Giulia LATTANZI , Iain LINGARD , Qingyian LIU , Jonathan D. LOW , Vu Van MA , Ana E. MINATTI , Alfonso POZZAN , Corey REEVES , Aaron C. SIEGMUND , Sabrina TASSINI , Federica TONELLI , Mary WALTON
IPC: C07D487/04 , A61P3/04 , C07D471/04 , C07D498/04
Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
-
公开(公告)号：US20200030324A1
公开(公告)日：2020-01-30
申请号：US16428163
申请日：2019-05-31
Applicant: Amgen Inc.
Inventor： Shon BOOKER , John Gordon ALLEN , Brian Alan LANMAN , Ryan Paul WURZ , Ning CHEN , Victor J. CEE , Patricia LOPEZ , Aaron C. SIEGMUND , Michael D. BARTBERGER
IPC: A61K31/497 , C07K16/28
Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20240327461A1
公开(公告)日：2024-10-03
申请号：US18497081
申请日：2024-06-11
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Michael J. FROHN , Brian Alan LANMAN , Anthony B. REED , Leslie P. MIRANDA , John Gordon ALLEN , Alexander J. PICKRELL , Aaron C. SIEGMUND , Lewis D. PENNINGTON , Bryant YANG
CPC classification number: C07K7/08 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , A61K38/00 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US20220395504A1
公开(公告)日：2022-12-15
申请号：US17363878
申请日：2021-06-30
Applicant: Amgen Inc.
Inventor： John Gordon ALLEN , Jennifer Rebecca ALLEN , Ana Elena MINATTI , Qiufen XUE , Ryan Paul WURZ , Christopher M. TEGLEY , Alexander J. PICKRELL , Thomas T. NGUYEN , Vu Van MA , Patricia LOPEZ , Longbin LIU , David John KOPECKY , Michael J. FROHN , Ning CHEN , Jian Jeffrey CHEN , Aaron C. SIEGMUND , Albert AMEGADZIE , Nuria A. TAMAYO , Shon BOOKER , Clifford GOODMAN , Mary WALTON , Nobuko NISHIMURA , Youngsook SHIN , Jonathan D. LOW , Victor J. CEE , Anthony B. REED , Hui-Ling WANG , Brian Alan LANMAN
IPC: A61K31/517 , A61P35/00 , A61K31/4985 , A61K39/395 , C07D403/04 , C07D471/04
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20210261619A1
公开(公告)日：2021-08-26
申请号：US17160819
申请日：2021-01-28
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Michael J. FROHN , Brian Alan LANMAN , Anthony B. REED , Leslie P. MIRANDA , John Gordon ALLEN , Alexander J. PICKRELL , Aaron C. SIEGMUND , Lewis D. PENNINGTON , Bryant YANG
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.025 seconds)
